NCT Number: NCT00320268
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Research Site, Little Rock, Arkansas, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient has a documented clinical diagnosis of Major Depressive Disorder.
- Be able to understand and comply with the requirements of the study.
- Able to understand and provide written informed consent
Exclusion criteria
- Patients (female) must not be pregnant or lactating
- Current or past diagnosis of stroke or transient ischemic attack (TIA).
Treatment and study plan
Primary outcomes
-
Change from randomization to Week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Secondary outcomes
-
Change from randomization to each assessment in the MADRS total score
-
MADRS response, defined as a ≥50% reduction from randomization in the MADRS total score at Week 6
Sponsors and collaborators
Lead sponsor
AstraZeneca
Industry
Registry information
Official study title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD
Acronym: MOONSTONE
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- May 3, 2006
- Registry last updated
- Mar 25, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
NCT03898297
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsStudy Evaluating Safety and Efficacy of Ropanicant in MDD Patients
NCT06126497
Behavior, Behavioral Symptoms
Bellflower, California, United States
View Trial DetailsCBT+ for Depression
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsTrial of Mirtazapine for Depression in IBD
NCT06309472
Behavior, Behavioral Symptoms
London, United Kingdom
View Trial Details